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Epidermal growth factor (EGF) and transforming growth
factor a (TGFx) are peptide growth hormones which are
known to regulate the proliferation of a variety of cells
(Carpenter & Cohen, 1979; Cohen, 1983; Marquardt et al.,
1983) including the gastrointestinal cells in rodents (Al-
Naffusi & Wright, 1982). Both of these peptides exert their
influences via the EGF receptor, a 170kDa phosphoglyco-
protein located across the cell membrane (Carpenter &
Cohen, 1979). The internal portion of this receptor bears a
close relationship to the v-erb-B oncogene product (Down-
ward et al., 1984), and it is likely that growth factors play a
role in oncogenesis (Burgess, 1985).
Certainly, a number of human neoplastic cell types have
been shown to express the EGF receptor to a variable degree
(Gusterson et al., 1984), and there is evidence that increased
expression is associated with a poor prognosis (Neal et al.,
1985; Sainsbury et al., 1987). Little work has been done on
colonic cancer, and although this tumour has been shown to
carry the receptor (Bradley et al., 1986; Yasui et al., 1988),
no firm association with prognostic factors has been estab-
lished. The aim of this study was to evaluate different
methods of immunohistochemical identification of EGF
receptors on human colonic cancers, and to investigate the
relationship between receptor expression and morphological
differentiation.
In all, 30 colonic carcinomas were studied, a portion being
taken immediately after resection and placed into liquid nit-
rogen. Frozen sections (6jm) were then cut, air dried over-
night, wrapped in aluminium foil and stored at -20°C. The
primary antibody used was mouse monoclonal anti-human
EGF receptor (Amersham) which is a class G2b immuno-
globulin produced using trypsinised A431 cells as the
immunogen (Waterfield et al., 1982). This antibody recog-
nises an antigenic determinant located on the extracellular
domain of the receptor (Mayes & Waterfield, 1984) but does
not compete with EGF for the ligand binding site (Gullick et
al., 1984).
In order to identify EGF receptors, three methods of
immunoperoxidase staining were evaluated: indirect, perox-
idase-antiperoxidase (PAP) and streptavidin-biotin (sABC)
(Guesdon et al., 1979; Polak & Van Noorden, 1983; Stern-
berger, 1979). The indirect method utilised peroxidase-con-
jugated rabbit anti-mouse immunoglobulin (Dakopatts) as
the second stage. For PAP staining, rabbit anti-mouse or
peroxidase-conjugated rabbit anti-mouse was followed by
peroxidase-mouse anti-peroxidase complex (Dakopatts).
Both of these systems were tried using single and double
techniques. The sABC method employed biotin-conjugated
rabbit anti-mouse immunoglobulin and streptavidin com-
plexed to biotinylated peroxidase (Dakopatts).
Various concentrations of all reagents were tested in order
to obtain optimum staining, the primary antibody being used
at 1:25, 1:50, 1:100, 1:200 and 1:400, and sections were
incubated at room temperature for 60 min. The rabbit
anti-mouse immunoglobulin was absorbed with 10% human
AB serum. Bound peroxidase was visualised using the di-
aminobenzamine/H202 reaction, and sections were counter-
stained with haematoxylin, dehydrated and mounted in DPX.
Two methods were used to block endogenous peroxidase
staining. The first consisted of periodic acid at 0.228% placed
on to the slides for 45 s after air drying (Kelly et al., 1987),
and the second involved making up the secondary antibody
in TBS containing glucose oxidase (1.5 u ml-') and glucose
(0.2M) (Koller et al., 1986).
Frozen sections of human placental tissue were used as
positive controls, and negative controls consisted of human
thyroid tissue (Damjanov et al., 1986; Gusterson et al., 1979).
In addition, every study slide was accompanied by a substitu-
tion control in which the primary antibody was replaced by
non-immune mouse IgG (Sigma). At histological examina-
tion, the intensity of peroxidase staining was graded as 0, +
or + +, and the colonic tumours were classified as well/
moderately or poorly differentiated. This was done by two
independent observers, and the grading of peroxidase stain-
ing intensity was performed without knowledge of the degree
of differentiation.
In all cases, background and non-specific staining was
minimal, although endogenous peroxidase in granulocytes
was encountered when blocking was not employed. The syn-
cytiotrophoblast of the placental tissue stained positively
using all techniques, but strongest staining was obtained
using the sABC method. No staining of formalin-fixed
placental tissue could be obtained by any means. In the
colonic tumours, positive staining was only obtained using
the double PAP system, with peroxidase-conjugated rabbit
anti-mouse as the secondary antibody, and the sABC method
(Table I). Of these two, the sABC technique gave more
intense, clearer staining and was much less time consuming.
The ideal dilutions were found to be 1:100 for the primary
antibody and 1:200 for the biotinylated rabbit anti-mouse.
Twenty-seven out of the 30 colonic cancers stained for EGF
receptor, and the staining was confined to the cytoplasm of the
neoplastic epithelial cells within the tumour. Both
the periodic acid and glucose oxidase methods were effective
in blocking endogenous peroxidase, but periodic acid
abolished all EGF receptor staining, even in placental tissue.
Table I Intensity ofimmunohistochemical staining for EGF receptor
on human placenta and colonic carcinoma using a variety of
methods
Placenta Colonic carcinoma
Single indirect + 0
Double indirect + + 0
Single PAP + + 0
Double PAP + + 0
Single PAP + PCRAM + + 0
Double PAP + PCRAM + + +
sABC + + + +
Results are based on the optimal primary antibody dilution of 1:100.
0, no staining; +, weak staining; + +, strong staining. PAP,
peroxidase-antiperoxidase; PCRAM, peroxidase-conjugated rabbit
anti-mouse; sABC, streptavidin-biotin complex.
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The glucose oxidase technique did not affect the
immunoreactivity of the EGF receptor on any of the sec-
tions. Intensity of staining was uniform throughout individ-
ual tumours, but it was significantly greater in the poorly
differentiated tumours when compared with the well/
moderately differentiated cancers (Table II).
In this study we have shown that EGF receptors can be
identified on the neoplastic cells of invasive human colonic
cancers using a well characterised commercially available
mouse monoclonal antibody, and we found the sABC system
to be the most suitable for this purpose. Less sensitive
methods were inadequate, and this presumably relates to the
low concentrations of receptor found in colonic carcinoma
using radioligand binding (Yasui et al., 1988).
EGF receptors have been demonstrated on a variety of
human tissues (Damjanov et al., 1986; Gusterson et al., 1984)
including squamous cell carcinoma (Ozanne et al., 1986), and
neoplasms of the lung (Veale et al., 1987), breast (Sainsbury
et al., 1985a), bladder (Neale et al., 1985) and stomach
(Yasui et al., 1988). In breast cancer, EGF receptor expres-
sion has been shown to be associated with an absence of
Table 11 Relationship between intensity ofimmunoperoxidase stain-
ing for EGF receptor and histological differentiation in colonic
carcinoma
Staining intensity
0/+ + +
Moderately/well differentiated 16 7
Poorly differentiated 0 7
X2 = 7.83 (With Yates'correction); P<0.01. Difference inpercentage
of tumours exhibiting + + staining = 69%, with a 95% confidence
interval of 50-88%.
oestrogen receptors, poor differentiation and increased risk of
early recurrence and death (Sainsbury et al., 1985b, c, 1987,
1988). Similarly, in bladder cancer EGF receptor positive
tumours tend to be invasive and poorly differentiated (Neale
et al., 1985), and in stomach carcinoma early tumours are
less likely to have receptors than advanced cancers (Yasui et
al., 1988).
Two previous studies have demonstrated EGF receptors in
colonic carcinoma (Bradley et al., 1986; Yasui et al., 1988).
In the first of these, radioligand binding, Western transfer
and indirect immunofluorescence were used, and moderately
well differentiated tumour cell lines were found to express
receptor activity to a greater extent than poorly differentiated
lines. There was, however, no detailed information on
naturally occurring tumours in this report (Bradley et al.,
1986). In the second study, no association between tumour
grade and EGF receptor expression could be demonstrated,
and only 77% of the tumours were receptor postive (Yasui et
al., 1988).
Clearly, there are contradictory findings regarding the
detection and significance of EGF receptors on human
tumours. This may indicate biological differences between
different tumour types, but it may also be related to the use
of antibodies which recognise different epitopes on the recep-
tor. Our data suggest that, when a highly sensitive technique
is used, the majority of colonic carcinomas can be shown to
express EGF receptors and that there is an association
between the degree of expression and histological
differentiation. Further elucidation of the prognostic
significance of this finding must await follow-up of larger
numbers of patients.
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